GlassScriptPhysician profile
Kenneth L Abbott
NPI 1306976949
$963.71
in general payments reported to CMS, 2019-2025
16 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.25 · 2020: $120 · 2021: $180 · 2022: $212 · 2023: $244 · 2024: $63.39 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $281 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $280.85 |
| Education | $157.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $298.12 | 2020-2023 | Darzalex |
| Aveo Pharmaceuticals, INC. | $183.17 | 2022-2023 | Fotivda |
| E.R. Squibb & Sons, L.L.C. | $107.38 | 2021-2025 | Reblozyl, Opdivo |
| Merck Sharp & Dohme LLC | $80.57 | 2019-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Gilead Sciences, INC. | $36.17 | 2021-2022 | |
| Abbvie INC. | $32.30 | 2025 | |
| Geron Corporation | $30.29 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $27.40 | 2023 | Libtayo |
| Amgen INC. | $26.12 | 2022 | |
| Exelixis INC. | $25.01 | 2021 | |
| G1 Therapeutics, INC. | $23.76 | 2022 | |
| Lilly USA, LLC | $23.54 | 2023 | Jaypirca |
| Coherus Oncology, INC. | $23.53 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.02 | 2022 | |
| Daiichi Sankyo INC. | $15.33 | 2025 | Injectafer |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $15.00 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.